{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"35"}],"units":"Participants"}],"groups":[{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 70 mg QD for 28 days and lenalidomide 15 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"BG000","title":"Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 70 mg QD for 28 days and lenalidomide 20 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"BG001","title":"Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 100 mg QD for 28 days and lenalidomide 20 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"BG002","title":"Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 100 mg QD for 28 days and lenalidomide 25 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"BG003","title":"Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 140 mg QD for 28 days and lenalidomide 25 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22). Cohort includes 4 participants treated for dose -finding phase and 13 participants treated in dose expansion phase.","id":"BG004","title":"Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.75","value":"66.2"},{"groupId":"BG001","spread":"4.73","value":"69.3"},{"groupId":"BG002","spread":"11.14","value":"63.0"},{"groupId":"BG003","spread":"5.92","value":"69.7"},{"groupId":"BG004","spread":"8.06","value":"59.3"},{"groupId":"BG005","spread":"9.19","value":"63.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"}]}],"title":"21 - 45 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"20"}]}],"title":"46 - 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"12"}]}],"title":"66 - 75 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"}]}],"title":">75 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"18"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"17"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"16"},{"groupId":"BG005","value":"34"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"}]}],"title":"Asian"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"6"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"6"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"5"}]}],"title":"Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"18"}]}],"title":"Not assessed"}],"description":"The ISS is an updated staging system for multiple myeloma. ISS divides multiple myeloma into three stages, which indicate the effect the disease is having on the body and how quickly or slowly it may develop. The ISS is based on the levels of blood proteins beta-2 microglobulin (β2M) and albumin. Stage I= β2M: \\<3.5 mg/L, albumin: \\>=3.5 g/dL; Stage II= β2M level: \\< 3.5 mg/L and albumin: \\< 3.5 g/dL, or β2M =3.5 to 5.5 mg/dL; Stage III: β2M level: \\>=5.5 mg/L.","paramType":"NUMBER","title":"International Staging System (ISS)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"9"}]}],"title":"Stage IA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]}],"title":"Stage IB"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"7"}]}],"title":"Stage IIA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]}],"title":"Stage IIB"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"11"}]}],"title":"Stage IIIA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]}],"title":"Stage IIIB"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"8"}]}],"title":"Not Assessed"}],"description":"Myeloma is classified into 3 stages. Stage I: hemoglobin (Hb) \\>10g/dL, normal calcium levels, normal skeletal survey or single plasmacytoma or osteoporosis, serum paraprotein level\\<5g/dL if immunoglobulin G(IgG), \\<3g/dL if IgA, urinary light chain excretion\\<4g/24h. Stage II: fulfilling the criteria of neither I nor III. Stage III: Hb\\<8.5g/dL, high calcium \\>12mg/dL, Skeletal survey of 3 or more lytic bone lesions, serum paraprotein \\>7g/dL if IgG,\\>5g/dL if IgA, urinary light chain excretion \\>12g/24h. Each stage further subdivided: A= serum creatinine \\<2mg/dL and B= serum creatinine \\>2mg/dL.","paramType":"NUMBER","title":"Durie-Salmon Staging System","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2","upperLimit":"18","value":"4.9"},{"groupId":"BG001","lowerLimit":"1","upperLimit":"5","value":"4.0"},{"groupId":"BG002","lowerLimit":"7","upperLimit":"11","value":"7.5"},{"groupId":"BG003","lowerLimit":"1","upperLimit":"6","value":"5.2"},{"groupId":"BG004","lowerLimit":"1","upperLimit":"16","value":"3.7"},{"groupId":"BG005","lowerLimit":"1","upperLimit":"18","value":"4.4"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time from diagnosis to first dosing","unitOfMeasure":"years"}]}